RE:AIF posted in SedarPandora wrote: Does it mean we are only allowed to treat at PMH now ? or this REB approval opens up several sites for us ?
Annual Information Form is now posted in Sedar.
Theralase has entered into a Sponsored Research Agreement (“SRA”) with University Health Network (“UHN”) to support research activities related to Theralase’s patented, patent pending and/or proprietary PDC technology used primarily for the destruction of cancer. In January 2018, Theralase researchers, specifically UHN and the University of Toronto, received an Ontario Research Fund – Research Excellence (“ORFRE”) grant with a primary mandate of advancing personalized AntiCancer PDT for individual cancer patients to safely and effectively destroy their particular cancer, while maximizing quality of life for them. The ORFRE grant valued at $4.5 million, with financial and technical support provided by worldclass industrial and institutional partners, such as IBM Canada and Altera (Intel).Through the ORFRE grant, the Company hopes to leverage resources to create value for both cancer patients and shareholders, while advancing Theralase’s innovative technology through various preclinical and clinical stages with an objective of commercialization. In addition to the ORFRE, Theralase has entered into an SRA with UHN in which, Theralase and UHN collectively work together to evaluate Theralase’s patented and patent pending platform of novel Ruthenium (“Ru”) and Osmium based PDCs for new cancer indications, in various drug formulations, with and without Transferrin including lung and brain cancer as well as to research cancer vaccines.
In April, 2019, Theralase entered into a Clinical Research Agreement (“CRA”) with University Health Network and Dr. Girish Kulkarni as the principal investigator to complete Study II. The Study II will be performed at Princess Margaret Cancer Centre, UHN in Toronto, Ontario and will be carried out according to the Study II clinical protocol design.